(OTC: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, announced today the submission of its application for Marketing Authorization (MA) for Endari® to the Kuwait Drug and Food Control (KDFC). This is the first step in the registration of Endari® by the KDFC, which is responsible for the registration of pharmaceutical products in Kuwait. The KDFC has accepted Emmaus's request for fast-track review of Endari®, which is expected to take not more than twelve months. Endari®, Emmaus' prescription grade L-glutamine oral powder, is approved by the United States Food and Drug Administration for treating sickle cell disease in adult and pediatric patients five years of age and older.